{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T16:59:11Z","timestamp":1788454751910,"version":"build-2803163510"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,10,19]],"date-time":"2019-10-19T00:00:00Z","timestamp":1571443200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,10,19]],"date-time":"2019-10-19T00:00:00Z","timestamp":1571443200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s40264-019-00875-6","type":"journal-article","created":{"date-parts":[[2019,10,19]],"date-time":"2019-10-19T18:25:41Z","timestamp":1571509541000},"page":"111-117","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Occurrences and Outcomes of Immune Checkpoint Inhibitors-Induced Vitiligo in Cancer Patients: A Retrospective Cohort Study"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3309-9230","authenticated-orcid":false,"given":"Samy","family":"Babai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Laure","family":"Voisin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9lia","family":"Bertin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amandine","family":"Gouverneur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Le-Louet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,19]]},"reference":[{"key":"875_CR1","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ejca.2017.12.008","volume":"91","author":"FX Danlos","year":"2018","unstructured":"Danlos FX, Voisin AL, Dyevre V, et al. Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease. Eur J Cancer. 2018;91:21\u20139.","journal-title":"Eur J Cancer"},{"key":"875_CR2","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","volume":"54","author":"JM Michot","year":"2016","unstructured":"Michot JM, Bigenwald C, Champiat S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016;54:139\u201348.","journal-title":"Eur J Cancer"},{"key":"875_CR3","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1200\/JCO.2014.57.4756","volume":"33","author":"HE Teulings","year":"2015","unstructured":"Teulings HE, Limpens J, Jansen SN, et al. Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis. J Clin Oncol. 2015;33:773\u201381.","journal-title":"J Clin Oncol"},{"key":"875_CR4","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1001\/jamadermatol.2015.2707","volume":"152","author":"C Hua","year":"2016","unstructured":"Hua C, Boussemart L, Mateus C, et al. Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab. JAMA Dermatol. 2016;152:45\u201351.","journal-title":"JAMA Dermatol."},{"key":"875_CR5","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1093\/annonc\/mdp325","volume":"21","author":"P Quaglino","year":"2010","unstructured":"Quaglino P, Marenco F, Osella-Abate S, et al. Vitiligo is an independent favourable prognostic factor in stage III and IV metastatic melanoma patients: results from a single-institution hospital-based observational cohort study. Ann Oncol. 2010;21:409\u201314.","journal-title":"Ann Oncol"},{"key":"875_CR6","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/1346-8138.13520","volume":"44","author":"Y Nakamura","year":"2017","unstructured":"Nakamura Y, Tanaka R, Asami Y, et al. Correlation between vitiligo occurrence and clinical benefit in advanced melanoma patients treated with nivolumab: a multi-institutional retrospective study. J Dermatol. 2017;44:117\u201322.","journal-title":"J Dermatol"},{"key":"875_CR7","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.1016\/j.jaad.2017.08.028","volume":"78","author":"K Boniface","year":"2018","unstructured":"Boniface K, Dutriaux C, Prey S, et al. Vitiligo-like lesions in patients receiving antieprogrammed cell death-1 therapies are distinct from spontaneously occurring active vitiligo. J Am Acad Dermatol. 2018;78:e17\u20138.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"875_CR8","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.jdcr.2016.10.008","volume":"3","author":"E Yin","year":"2017","unstructured":"Yin E, Totonchy M, Leventhal J. Nivolumab-associated vitiligo-like depigmentation in a patient with acute myeloid leukemia: a novel finding. JAAD Case Rep. 2017;3(2):90\u20132.","journal-title":"JAAD Case Rep."},{"key":"875_CR9","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1016\/j.jdcr.2018.08.009","volume":"4","author":"C Kosche","year":"2018","unstructured":"Kosche C, Mohindra N, Choi JN. Vitiligo in a patient undergoing nivolumab treatment for non-small cell lung cancer. JAAD Case Rep. 2018;4:1042\u20134.","journal-title":"JAAD Case Rep"},{"key":"875_CR10","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/S1246-7820(99)80036-6","volume":"6","author":"A Spreux","year":"1999","unstructured":"Spreux A, Baldin B, Chichmanian RM. Pharmacovigilance in practice. Transfus Clin Biol. 1999;6:254\u20139.","journal-title":"Transfus Clin Biol"},{"key":"875_CR11","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","volume":"20","author":"EG Brown","year":"1999","unstructured":"Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf. 1999;20:109\u201317.","journal-title":"Drug Saf"},{"key":"875_CR12","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.lungcan.2017.04.019","volume":"109","author":"T Uenami","year":"2017","unstructured":"Uenami T, Hosono Y, Ishijima M, et al. Vitiligo in a patient with lung adenocarcinoma treated with nivolumab: a case report. Lung Cancer. 2017;109:42\u20134.","journal-title":"Lung Cancer"},{"key":"875_CR13","doi-asserted-by":"publisher","first-page":"247","DOI":"10.2165\/00128071-200708040-00008","volume":"8","author":"M Polat","year":"2007","unstructured":"Polat M, Yal\u00e7in B, Alli N. Vitiligo at the site of radiotherapy for nasopharyngeal carcinoma. Am J Clin Dermatol. 2007;8:247\u20139.","journal-title":"Am J Clin Dermatol"},{"key":"875_CR14","doi-asserted-by":"publisher","first-page":"254","DOI":"10.4103\/2229-5178.115542","volume":"4","author":"M Phiske","year":"2013","unstructured":"Phiske M. Radiotherapy induced keobernisation of vitiligo. Indian Dermatol Online J. 2013;4:254\u20135.","journal-title":"Indian Dermatol Online J."},{"key":"875_CR15","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(17)31601-X","volume":"390","author":"J Schachter","year":"2017","unstructured":"Schachter J, Ribas A, Long GV, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet. 2017;390:1853\u201362.","journal-title":"Lancet"},{"key":"875_CR16","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1097\/00002371-199601000-00009","volume":"19","author":"SA Rosenberg","year":"1996","unstructured":"Rosenberg SA, White DE. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. J Immunother Emphasis Tumor Immunol. 1996;19:81\u20134.","journal-title":"J Immunother Emphasis Tumor Immunol"},{"key":"875_CR17","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1016\/0959-8049(94)90493-6","volume":"30A","author":"C Scheibenbogen","year":"1994","unstructured":"Scheibenbogen C, Hunstein W, Keilholz U. Vitiligo-like lesions following immunotherapy with IFN alpha and IL-2 in melanoma patients. Eur J Cancer. 1994;30A:1209\u201311.","journal-title":"Eur J Cancer"},{"key":"875_CR18","doi-asserted-by":"publisher","first-page":"290","DOI":"10.3389\/fendo.2017.00290","volume":"8","author":"E Baldini","year":"2017","unstructured":"Baldini E, Odorisio T, Sorrenti S, et al. Vitiligo and autoimmune thyroid disorders. Front Endocrinol (Lausanne). 2017;8:290.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"875_CR19","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.canlet.2019.04.018","volume":"456","author":"A Teufel","year":"2019","unstructured":"Teufel A, Zhan T, H\u00e4rtel N, et al. Management of immune related adverse events induced by immune checkpoint inhibition. Cancer Lett. 2019;456:80\u20137.","journal-title":"Cancer Lett."},{"key":"875_CR20","doi-asserted-by":"publisher","first-page":"342","DOI":"10.3747\/co.25.4235","volume":"25","author":"G Myers","year":"2018","unstructured":"Myers G. Immune-related adverse events of immune checkpoint inhibitors: a brief review. Curr Oncol. 2018;25:342\u20137.","journal-title":"Curr Oncol."},{"key":"875_CR21","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1158\/2326-6066.CIR-16-0237","volume":"5","author":"G De Velasco","year":"2017","unstructured":"De Velasco G, Je Y, Boss\u00e9 D, et al. Comprehensive meta-analysis of key immune-related adverse events from CTLA-4 and PD-1\/PD-L1 inhibitors in cancer patients. Cancer Immunol Res. 2017;5:312\u20138.","journal-title":"Cancer Immunol Res"},{"key":"875_CR22","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s00432-018-2819-x","volume":"145","author":"A Indini","year":"2019","unstructured":"Indini A, Di Guardo L, Cimminiello C, et al. Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma. J Cancer Res Clin Oncol. 2019;145:511\u201321.","journal-title":"J Cancer Res Clin Oncol"},{"key":"875_CR23","unstructured":"The reorganisation of European pharmacovigilance. Part 2. From spontaneous reports to agency reviews and decisions. Prescrire Int. 2015;24(157):50\u20134."},{"key":"875_CR24","unstructured":"\u00a9 Les immunoth\u00e9rapies sp\u00e9cifiques dans le traitement des cancers\u2014rapport. France. Collection \u00e9tats des lieux et des connaissances, INCa (Institut national du cancer); 2018."},{"key":"875_CR25","first-page":"5","volume":"11","author":"S Berthet","year":"2011","unstructured":"Berthet S, Olivier P, Montastruc JL, Lapeyre-Mestre M. Drug safety of rosiglitazone and pioglitazone in France: a study using the French PharmacoVigilance database. Clin Pharmacol. 2011;11:5.","journal-title":"Clin Pharmacol"},{"issue":"1","key":"875_CR26","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1111\/j.1365-2125.2012.04185.x","volume":"74","author":"G Moulis","year":"2012","unstructured":"Moulis G, Sommet A, Durrieu G, et al. Trends of reporting of \u2018serious\u2019 vs. \u2018non-serious\u2019 adverse drug reactions over time: a study in the French PharmacoVigilance Database. Br J Clin Pharmacol. 2012;74(1):201\u20134.","journal-title":"Br J Clin Pharmacol."},{"issue":"1","key":"875_CR27","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/j.1365-2125.2011.03944.x","volume":"72","author":"P Gavaza","year":"2011","unstructured":"Gavaza P, Brown CM, Lawson KA, et al. Influence of attitudes on pharmacists\u2019 intention to report serious adverse drug events to the Food and Drug Administration. Br J Clin Pharmacol. 2011;72(1):143\u201352.","journal-title":"Br J Clin Pharmacol."}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-019-00875-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40264-019-00875-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-019-00875-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,17]],"date-time":"2020-10-17T23:18:58Z","timestamp":1602976738000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40264-019-00875-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,19]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["875"],"URL":"https:\/\/doi.org\/10.1007\/s40264-019-00875-6","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,19]]},"assertion":[{"value":"19 October 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"No sources of funding were used to assist in the preparation of this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Samy Babai, Anne-Laure Voisin, C\u00e9lia Bertin, Amandine Gouverneur and Herv\u00e9 Le Louet have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}